Copyright
©The Author(s) 2025.
World J Gastroenterol. Aug 28, 2025; 31(32): 109383
Published online Aug 28, 2025. doi: 10.3748/wjg.v31.i32.109383
Published online Aug 28, 2025. doi: 10.3748/wjg.v31.i32.109383
Figure 3 Kaplan-Meier curves of circulating tumor DNA dynamics and postoperative recurrence-free survival in 31 patients sampled before and after neoadjuvant therapy.
The median recurrence-free survival (RFS) of 20.2 months for the group whose circulating tumor DNA (ctDNA) changed from positive to negative after neoadjuvant therapy (NAT) was not significantly different from the median RFS of 18 months for the group whose ctDNA remained negative during NAT (P = 0.862). ctDNA: Circulating tumor DNA; RFS: Recurrence-free survival.
- Citation: Murakami T, Imamura M, Kimura Y, Watanabe K, Shinohara Y, Nakamura T, Low SK, Motoya M, Kawakami Y, Masaki Y, Kubo T, Yoshida M, Yoshida E, Kato T, Kukita K, Kyuno D, Takemasa I. Role of preoperative circulating tumor DNA in predicting occult metastases in resectable and borderline resectable pancreatic ductal adenocarcinoma. World J Gastroenterol 2025; 31(32): 109383
- URL: https://www.wjgnet.com/1007-9327/full/v31/i32/109383.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i32.109383